17-Jan-2019 - Merck KGaA

Merck Welcomes Ten New Startups to its Innovation Center

Merck announced the ten startups that will be joining the seventh intake of its Accelerator program at the Merck Innovation Center in Darmstadt. The teams come from nine different countries, making 2019 the most international intake in the Merck Accelerator’s history. They were chosen from a total of 565 applications, coming from startups based in 68 countries across the world.

“We are confident that inviting such a diverse group of collaboration-ready startups can lead to outstanding partnerships. We believe that startups and a company such as Merck can mutually benefit a lot from working together. Partnering with startups, we connect with new external ideas while we simultaneously help them to take off. Bringing curious and expert minds together is a tremendous opportunity to create innovations beyond our current scope,” said Michael Gamber, Head of the Merck Innovation Center.

The ten selected startups will join the Merck Accelerator for the program’s three-month duration. For the first time since the launch of the program, some of the participating startups will also have the opportunity to extend their stay by joining the company’s China Innovation Hub in Shanghai, which will give them the opportunity to access the Chinese market.

The Merck Accelerator welcomes startups operating in healthcare, life science and performance materials, as well as emerging areas such as bio-sensing and interfaces or liquid biopsy, which represent the Innovation Fields that the Merck Innovation Center is focusing on. This year’s program includes, for example, Nextbiotics – a startup focusing on antibiotic-resistant bacteria and microbiomes: Nextbiotics is developing a biotechnology platform that engineers bacteriophages to target antibiotic-resistant bacteria. The startup envisions using its technology to precisely modulate the microbiome with applications in the prevention and treatment of infections for humans and animals. The other startup teams (please also check the adjacent fact sheet) joining the Merck Accelerator program are also working on solutions that could make a positive difference in people’s lives. From affordable point-of-care diagnostic devices through intelligent solutions to developing 3D bioprinted skin, to even analysing patients’ tumour samples in order to identify their level of drug resistance and determine the best type of cancer treatment.

The ten startups joining the Merck Accelerator in Darmstadt, Germany:

  • Ourotech, Canada
  • Nanosor, Germany
  • Hafnium Labs, Denmark
  • MEVIA, Sweden
  • Next Big Innovation Labs, India
  • Dicronis, Switzerland
  • iXensor, Taiwan
  • Nextbiotics, USA
  • Levels Diagnostics, Netherlands
  • MicroX Labs (Pratimesh Labs), India
More about Merck
More about Dicronis
  • Companies


    At Dicronis, we strive to enhance the quality-of-life of patients with our innovative technology. ​The first product in our pipeline, Lymphit, measures patient’s lymphatic function in a safe, home-based and highly scalable manner. The initial indication of Lymphit is the earliest possible d ... more

More about Ourotech
  • Companies


    A patient that is diagnosed with cancer today will have a genetic screen on their tumor sample to determine their subtype of cancer. Based on the cancer subtype, they are given a first line of treatment. If that doesn't work, they are given a second line of treatment. If that doesn't work, ... more

More about Mevia
  • Companies

    Mevia AB

    Through its broad portfolio of connected technologies, data analytics and in-house expertise, mevia improves patient adherence to medication. Whether you are an innovative pharmaceutical company, a medical research organization or a natural health company, we can help you empower your users ... more

More about Next Big Innovation Labs
  • Companies

    Next Big Innovation Labs Pvt. Ltd.

    We are a 3D Bioprinting Company based in Bangalore and We Proudly Make In India Our Vision is to create Organs within a Laboratory using the disruptive technology of 3D Bioprinting. Our team, with expertise in 3D Printing, Biotechnology and Pharmaceuticals, endeavours to create a parad ... more

More about iXensor
  • Companies


    iXensor Co. Ltd. is based in Taipei, Taiwan and was founded in 2012. Our three co-founders, Alan Tsai, the CEO, Jerry Chen, the CMO, Carson Chen, the CTO, first met in Stanford-Taiwan Biomedical Fellowship Program (STB) and came up with the idea of PixoTest technology. This breakthrough ide ... more

More about Levels Diagnostics
  • Companies

    Levels Diagnostics

    Levels Diagnostics is developing a rapid diagnostic tool that allows medical healthcare professionals to assess the nature of an infectious disease, being bacterial or viral. Our disposable and affordable tool will provide an accurate diagnosis within minutes. This tool will reduce antibiot ... more